F. Hoffmann-La Roche Ltd
Profile managed by Bizz IdDescription
Products
45 productsRG6631. mAb targeting TL1A. Ulcerative colitis and Crohn's disease in Phase 3; atopic dermatitis and rheumatoid arthritis in Phase 2; MASH in Phase 1b.
Under development
Finished product (FDF)
Verified on 2026-10-21
RG6149. COPD. Phase 3.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Tecentriq. Anti-PD-L1 cancer immunotherapy; intravenous and subcutaneous. NSCLC and SCLC, hepatocellular carcinoma, urothelial cancer, PD-L1-positive TNBC, BRAF V600 melanoma and alveolar soft part sarcoma. Filings in dMMR/MSI-H colon and oesophageal cancer.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Avastin. Monoclonal antibody targeting VEGF-A. Colorectal, non-small cell lung, kidney, ovarian, cervical and breast cancer; glioblastoma. Neurofibromatosis type 2 approved June 2026.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
RG6160. Bispecific anti-FcRH5/CD3. Relapsed/refractory multiple myeloma (2-4L). Phase 3.
Under development
Finished product (FDF)
Verified on 2026-10-21
DLL3 trispecific. Solid tumors. Phase 1. Chugai programme.
Under development
Finished product (FDF)
Verified on 2026-10-21
Hepatocellular carcinoma. Phase 1. Chugai programme.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: PiaSky. Recycling monoclonal antibody inhibiting C5; subcutaneous every four weeks. Paroxysmal nocturnal haemoglobinuria. Phase 3 in atypical haemolytic uraemic syndrome.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Pulmozyme. Recombinant human deoxyribonuclease 1. Improves lung function in cystic fibrosis.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Hemlibra. Bispecific factor IXa- and factor X-directed antibody. Prophylaxis in haemophilia A with or without factor VIII inhibitors. Phase 3 in type 3 von Willebrand disease.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
RG6237 (GYM329). Recycling and antigen-sweeping anti-latent myostatin monoclonal antibody. Obesity. Phase 2.
Under development
Finished product (FDF)
Verified on 2026-10-21
RG6411. Anti-CCR8 antibody. Solid tumors. Phase 1.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: NeoRecormon. Anaemia due to chronic kidney disease, chemotherapy-induced anaemia, prevention of anaemia in premature babies and pre-surgery blood donation.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Vabysmo. Bispecific antibody neutralising Ang-2 and VEGF-A, intravitreal. Neovascular AMD, diabetic macular edema and macular edema after retinal vein occlusion. Phase 3 in myopic CNV.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Columvi. CD20xCD3 T-cell engaging bispecific antibody. Relapsed or refractory diffuse large B-cell lymphoma after two or more lines. Phase 3 in first line and in mantle cell lymphoma.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Mircera. Stimulates red blood cell production. Symptomatic anaemia associated with chronic kidney disease in adults.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Lunsumio. CD20xCD3 T-cell engaging bispecific antibody. Relapsed or refractory follicular lymphoma after two or more lines. Phase 3 in follicular lymphoma and DLBCL; SC formulation in Phase 2 in SLE.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Gazyva/Gazyvaro. Engineered anti-CD20 monoclonal antibody. Chronic lymphocytic leukaemia and follicular lymphoma. In development/filed in lupus nephritis, SLE, childhood idiopathic nephrotic syndrome and membranous nephropathy.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Ocrevus. Targets CD20-positive B cells; twice-yearly dosing. Relapsing MS, clinically isolated syndrome (US) and primary progressive MS.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
RG6881. Fibroblast growth factor 21 (FGF21) analog. MASH F2-F3 and F4. Phase 3.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Perjeta. Targets the HER2 receptor. Neoadjuvant, adjuvant and advanced HER2-positive breast cancer, with Herceptin and chemotherapy.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Phesgo. Fixed-dose combination of two monoclonal antibodies with hyaluronidase, subcutaneous. Early and metastatic HER2-positive breast cancer.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Polivy. Antibody-drug conjugate targeting CD79b. Diffuse large B-cell lymphoma, first line and relapsed or refractory.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
RG7935. Anti-alpha-synuclein antibody. Early Parkinson's disease. Phase 3. Partner: Prothena.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Susvimo. VEGF inhibitor, port delivery system. Neovascular age-related macular degeneration (US); diabetic macular edema and diabetic retinopathy in development/filed.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brainshuttle construct directed at CD20. Multiple sclerosis. Phase 1.
Under development
Finished product (FDF)
Verified on 2026-10-21
VEGF x IL6 DutaFab dual-target. Diabetic macular edema. Phase 1.
Under development
Finished product (FDF)
Verified on 2026-10-21
Anti-Tie2 agonist. Diabetic macular edema. Phase 1.
Under development
Finished product (FDF)
Verified on 2026-10-21
CD19 x CD3 bispecific. Systemic lupus erythematosus. Phase 1.
Under development
Finished product (FDF)
Verified on 2026-10-21
cMET antibody-drug conjugate. Solid tumors. Phase 1. Managed by MediLink.
Under development
Finished product (FDF)
Verified on 2026-10-21
p40 x TL1A bispecific antibody. Ulcerative colitis. Phase 2b. In collaboration with Pfizer.
Under development
Finished product (FDF)
Verified on 2026-10-21
DLL3 antibody-drug conjugate. Small cell lung cancer. Phase 1. Managed by Innovent.
Under development
Finished product (FDF)
Verified on 2026-10-21
B7H3 antibody-drug conjugate. Solid tumors. Phase 1. Managed by MediLink.
Under development
Finished product (FDF)
Verified on 2026-10-21
CDH17 antibody-drug conjugate. Colorectal cancer. Phase 1. In collaboration with Hansoh Pharma.
Under development
Finished product (FDF)
Verified on 2026-10-21
Dual-target anti-TSLP:IL33. COPD/asthma. Phase 1. Managed by Qyuns Therapeutics.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: MabThera / Rituxan (US, Japan, Canada). Follicular lymphoma, DLBCL, chronic lymphocytic leukaemia, rheumatoid arthritis, pemphigus vulgaris, GPA/MPA.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: MabThera SC / Rituxan Hycela (US). Rituximab hyaluronidase, subcutaneous. Follicular lymphoma, DLBCL and chronic lymphocytic leukaemia.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Enspryng. Humanised monoclonal antibody targeting the IL-6 receptor; subcutaneous. AQP4 antibody-positive neuromyelitis optica spectrum disorder. Phase 3 in MOGAD, autoimmune encephalitis and thyroid eye disease.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Actemra/RoActemra. Anti-IL-6 receptor therapy; IV and SC formulations. Rheumatoid arthritis, polyarticular and systemic juvenile idiopathic arthritis, giant cell arteritis, CAR-T-induced cytokine release syndrome and severe or critical COVID-19 in hospitalised patients.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Herceptin. Monoclonal antibody. HER2-positive early and advanced breast cancer, advanced HER2-positive gastric cancer.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Herceptin SC / Herceptin Hylecta (US). Trastuzumab hyaluronidase, subcutaneous. HER2-positive early and advanced breast cancer.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Kadcyla. Antibody-drug conjugate targeting HER2. Advanced and residual-disease early HER2-positive breast cancer. Phase 3 with atezolizumab in high-risk early breast cancer.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
RG6102. Brainshuttle bispecific 2+1 monoclonal antibody targeting amyloid-beta. Early Alzheimer's disease. Phase 3.
Under development
Finished product (FDF)
Verified on 2026-10-21
RG6179. Anti-IL-6 mAb. Uveitic macular edema. Phase 3.
Under development
Finished product (FDF)
Verified on 2026-10-21
RG6512 (NXT007). Bispecific targeting factor IXa and factor X. Haemophilia A. Phase 3. Partner: Chugai.
Under development
Finished product (FDF)
Verified on 2026-10-21